🎙️ Podcast on the topic
1. Basics & mode of action
The endocannabinoid system (ECS) plays a central role in regulating inflammation, pain perception and immune function, all areas that matter in multiple sclerosis.
The endocannabinoid system
Every person has an endocannabinoid system of their own with CB1 and CB2 receptors. These receptors are found throughout the nervous system and the immune system.
How might cannabis work in MS?
In multiple sclerosis the immune system attacks the myelin sheaths of the nerve fibers. Cannabinoids may act on several levels:
-
Neuroprotective - protecting nerve cells from further damage
-
Anti-inflammatory - reducing the immune response
-
Muscle-relaxing - easing spasticity
-
Pain-relieving - improving quality of life
2. Cannabinoids explained
The cannabis plant contains more than 100 different cannabinoids. The two most important ones for MS treatment are THC and CBD.
THC (tetrahydrocannabinol)
- Psychoactive effect
- Strong pain relief
- Appetite-stimulating
- Muscle-relaxing
- Sleep-promoting
CBD (cannabidiol)
- Not psychoactive
- Anti-inflammatory
- Anxiety-relieving
- Neuroprotective
- No dependence
"For many MS patients the combination of THC and CBD in a 1:1 ratio has proven particularly effective, because the active ingredients reinforce each other and soften side effects."— Current treatment recommendations, 2024
3. Studies & evidence
The scientific evidence for the use of cannabis in MS keeps growing. Here is an overview of important study results:
Cannabis-based medicines in MS spasticity
An analysis of 17 randomized controlled trials with 3,161 participants showed that cannabinoids significantly reduce patient-reported spasticity.
Sativex® in treatment-resistant spasticity
The SAVANT study examined the effectiveness of the nabiximols spray in patients who did not respond to other therapies.
4. MS symptoms & cannabis
Various MS symptoms may be treated with cannabis-based therapies. Effectiveness varies by symptom:
| Symptom | Evidence | Cannabinoids used |
|---|---|---|
| Spasticity | High | THC/CBD (1:1) |
| Neuropathic pain | High | THC-dominant |
| Sleep disorders | Moderate | THC (evening) |
| Bladder dysfunction | Moderate | THC/CBD |
| Tremor | Limited | CBD-dominant |
5. Overview of varieties
In Germany various cannabis varieties are approved for medical purposes. Choosing the right variety matters for treatment success. Which products exist and are permitted differs from country to country.
For spasticity & sleep
Higher myrcene content, relaxing, ideal for the evening
For fatigue & mood
Higher limonene content, activating, ideal for daytime
For beginners
Milder effect, good tolerability, can be used all day
6. Legal status & prescription (Germany)
Legal for medical use in Germany since March 2017 (the rules differ in every country)
In Germany, medical cannabis can be prescribed by any doctor (except veterinarians and dentists) on a narcotics prescription (BtM). In other countries different rules apply, and in many it is not available or not permitted. Please check the legal situation where you live.
The route to a prescription (Germany)
Talk to your doctor
Discuss cannabis as a treatment option with your neurologist or general practitioner.
Application to the health insurer
For serious conditions such as MS, applications are often approved.
Narcotics prescription
After approval you receive a narcotics prescription.
Pharmacy
The prescription is filled at the pharmacy - delivery time about 2-5 days.
Important notice
Cost coverage by the health insurer is not automatic. An informal application with a medical justification is required. The approval rate in MS is over 70%. This describes the situation in Germany.
7. 📚 Full research reports
Here you will find the full scientific analyses and study reports on cannabis and multiple sclerosis. All information is based on current research.
In-depth cannabis study review in multiple sclerosis
Introduction
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disease of the central nervous system that affects about 2.8 million people worldwide. The search for effective therapies to relieve the many symptoms and to slow the course of the disease is a central field of research. In recent years cannabis and its derivatives have attracted growing scientific interest as potential therapeutics in MS.
The endocannabinoid system and MS
The endocannabinoid system (ECS) plays a fundamental role in modulating inflammation, pain perception and neuroprotection. Significant changes in the ECS have been observed in MS patients, including raised levels of the endocannabinoid anandamide in the cerebrospinal fluid during active inflammatory phases.
The cannabinoid receptors CB1 and CB2 are distributed throughout the nervous system and the immune system. CB1 receptors are found mainly in the brain and spinal cord and modulate synaptic transmission. CB2 receptors are expressed mostly on immune cells and regulate inflammatory processes.
Nabiximols (Sativex®) – the gold standard
Nabiximols, an oromucosal spray with a THC:CBD ratio of about 1:1, is the best-studied cannabis-based medicine for MS. It has been approved in more than 30 countries for the treatment of MS-associated spasticity.
SAVANT study (2024)
The most recent randomized controlled trial with 445 patients showed a significant improvement in spasticity (measured with the Numeric Rating Scale) compared with placebo. The average reduction was 2.5 points after 12 weeks of treatment.
Mechanisms of action in MS symptoms
Spasticity
Cannabis acts through presynaptic CB1 receptor activation, which reduces excessive glutamatergic neurotransmission. This leads to a decrease in raised muscle tone. Meta-analyses show that about 45-50% of patients experience a clinically meaningful reduction in spasticity.
Neuropathic pain
CB1 receptors modulate descending pain inhibition and reduce peripheral sensitization. Studies report an average pain reduction of 30-50% in MS patients with neuropathic pain.
Bladder dysfunction
Cannabinoids can reduce overactivity of the detrusor muscle and increase bladder capacity. In clinical studies 25-40% of patients reported an improvement in urinary frequency and urge incontinence.
Sleep disorders
The sedating properties of THC, combined with the anxiolytic effect of CBD, may improve sleep. Studies show improved sleep quality in 60-70% of treated patients.
THC versus CBD: a differentiated view
| Property | THC (Δ9-tetrahydrocannabinol) | CBD (cannabidiol) |
|---|---|---|
| Receptor binding | Full CB1/CB2 agonist | Negative allosteric modulator |
| Psychoactivity | Yes (dose-dependent) | No |
| Spasticity | Strongly effective | Moderately effective |
| Neuroprotection | Present | Pronounced |
| Anti-inflammatory effect | Moderate | Strong |
| Dependence potential | Low to moderate | Not present |
Current evidence and level of evidence
Cannabis-based medicines in MS
A systematic review of 25 randomized controlled trials with a total of 3,763 participants. Moderate evidence of effectiveness in spasticity and chronic pain. Low evidence of improvements in bladder function and tremor.
5-year follow-up of nabiximols
A prospective observational study of 297 patients over 5 years showed sustained effectiveness without development of tolerance. 78% of the initial responders still showed a clinically meaningful improvement in spasticity after 5 years.
Safety profile and side effects
The most common side effects of cannabis-based medicines in MS include:
-
Dizziness and light-headedness - occurs in about 25-30% of patients, usually mild and temporary
-
Fatigue - in 15-20% of patients, can be minimized with evening dosing
-
Dry mouth - common, but well tolerated
-
Cognitive impairment - possible at higher THC doses, reversible after dose reduction
Good to know
No development of tolerance was observed in long-term studies. Most side effects are dose-dependent and can be avoided by slow titration.
Practical recommendations for use
Dosing strategy: "Start low, go slow" - start with the lowest available dose and increase slowly until the desired effect is reached with tolerable side effects.
Timing: In spasticity an evening dose can help to reduce the nighttime spasticity peak and to promote sleep.
Combination therapy: Cannabis-based medicines should be seen as a supplement to existing antispasticity therapy, not as a replacement.
Future perspectives
Research is increasingly focusing on specific cannabinoid formulations and new routes of administration. Promising developments include:
- Transdermal patches for steady plasma levels
- Liposomal CBD formulations with improved bioavailability
- Combinations with other neuroprotective substances
- Personalized treatment approaches based on genetic markers
Conclusion
Cannabis-based medicines, especially nabiximols, have established themselves as an effective treatment option for MS-associated spasticity. The evidence for other symptoms such as neuropathic pain is promising but requires further research. Careful patient selection, slow dose titration and regular monitoring are decisive for treatment success.
THC and CBD: specific effects in MS
Molecular basics
Δ9-tetrahydrocannabinol (THC) is the main psychoactive component of cannabis. It binds as a partial agonist to CB1 and CB2 receptors. This binding leads to inhibition of adenylyl cyclase and a reduction of the intracellular cAMP level.
Cannabidiol (CBD), by contrast, has a more complex pharmacology. It acts as a negative allosteric modulator at the CB1 receptor, which means it can weaken the effect of endocannabinoids and THC. In addition CBD interacts with serotonin 5-HT1A receptors, GPR55 and TRPV1 channels.
Clinical studies: THC-dominant preparations
Dronabinol (synthetic THC) has been studied in several MS trials. A randomized controlled trial with 630 patients showed a significant reduction in spasticity (Ashworth scale) compared with placebo after 15 weeks of treatment.
Clinical studies: CBD-dominant preparations
Highly purified CBD (Epidiolex) has received approvals primarily for epilepsy. In MS the data are limited, but preclinical studies show promising neuroprotective and anti-inflammatory effects in the animal model of experimental autoimmune encephalomyelitis (EAE).
Synergistic effects: the entourage effect
The combination of THC and CBD shows better results in many studies than the individual substances. CBD can reduce the psychoactive side effects of THC, while THC increases the therapeutic potency. Additional cannabinoids such as CBG, CBC and terpenes (myrcene, limonene, linalool) contribute to the entourage effect.
Medical notice
This information does not replace medical advice. Before starting cannabis therapy, please consult your neurologist.
8. Frequently asked questions (FAQ)
Does the health insurer pay for cannabis in MS? ▼
In Germany, yes: in principle there is an entitlement to cost coverage for serious conditions such as MS (the "Cannabis Act"). The usual condition is that standard therapies were not sufficiently effective or were not tolerated. Your neurologist has to submit an application to the health insurer, which is very often approved for an MS indication. Rules in other countries differ.
Which cannabis variety is best for MS spasticity? ▼
The first choice is often the approved spray Sativex® (nabiximols), which contains THC and CBD in a 1:1 ratio. If flowers are prescribed, doctors often recommend indica-dominant varieties (e.g. Bedica, Tilray 22) for their muscle-relaxing effect. Sativa varieties are used rather for fatigue.
May I drive as a patient? ▼
In Germany, yes. For patients who receive cannabis on prescription, the "medication privilege" applies. You may take part in road traffic as long as there are no signs of impairment and you are "stabilized" on the treatment. During the titration phase you should refrain from driving. Always carry a copy of your current prescription. Rules differ in other countries.
How do CBD and THC work together? (entourage effect) ▼
CBD can soften unwanted side effects of THC (such as a racing heart or feelings of anxiety) without reducing the pain-relieving effect. That is why 1:1 preparations, or the combination of THC flowers and CBD oil, are particularly popular in MS.